BIOCQ — Biocept Share Price
0.000.00%
Last trade - 00:00- $0.00m
- -$4.46m
- $25.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -146.21% | ||
| Return on Equity | -138.6% | ||
| Operating Margin | -123.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.25 | 5.53 | 27.46 | 61.25 | 25.86 | 2.48 | 6.47 | 38.53% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular technologies intended to aid medical professionals in CSF analysis and central nervous system (CNS) disease management in patients with solid tumors. It offers and conducts its commercialized diagnostic assays, which include cell capture and enumeration, immunocytochemistry, fluorescent in situ hybridization (FISH), and next generation sequencing (NGS). It has commercialized its CNSide assays for detecting and characterizing many different carcinomas and melanoma. These assays utilize its dual cellular and ctDNA technology platforms and provide biomarker analysis from a patient’s CSF sample.
Directors
- Samuel Riccitelli CHM (62)
- Margaret Faye Wilson NEC (83)
- Michael Nall PRE (58)
- Timothy Kennedy CFO (63)
- Darrell Taylor SVP
- Michael Dugan SVP (59)
- Michael Terry SVP (66)
- Michael Brown CCO
- Antonio Paternostro VPR
- Gary Marchetti OTH
- Tom Nauman OTH
- Tim Schofield OTH
- David Hale DRC (72)
- Antonino Morales DRC
- Linda Rubinstein DRC (54)
- Marsha Chandler IND (76)
- Bruce Gerhardt IND (70)
- Ivor Royston IND (76)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- June 28th, 2013
- Public Since
- February 5th, 2014
- No. of Shareholders
- 11
- No. of Employees
- 50
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 2,626,026
- Address
- 9955 Mesa Rim Road, SAN DIEGO, 92121
- Web
- https://biocept.com/
- Phone
- +1 8583208200
- Contact
- Jody Cain
- Auditors
- RSM US LLP
Upcoming Events for BIOCQ
Similar to BIOCQ
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
What is the Biocept share price?
As of Today at 19:36 UTC, shares in Biocept are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Biocept share price performed this year?
Shares in Biocept last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the Biocept share price has underperformed the S&P500 Index by -100% over the past year.
What are the analyst and broker recommendations for Biocept?
The overall consensus recommendation for Biocept is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Biocept dividend yield?
Biocept does not currently pay a dividend.
Does Biocept pay a dividend?
Biocept does not currently pay a dividend.
When does Biocept next pay dividends?
Biocept does not currently pay a dividend.
How do I buy Biocept shares?
To buy shares in Biocept you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biocept?
As of the previous close price of $0.00, shares in Biocept had a market capitalisation of $0.00m.
Where are Biocept shares listed?
Here are the trading details for Biocept:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: BIOCQ
What kind of share is Biocept?
Based on an overall assessment of its quality, value and momentum Biocept is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biocept share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Biocept share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocept. Over the past six months, its share price has underperformed the S&P500 Index by -100%.
As of the last closing price of $0.00, shares in Biocept were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biocept PE Ratio?
The Biocept PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biocept?
Biocept's management team is headed by:
- Samuel Riccitelli - CHM
- Margaret Faye Wilson - NEC
- Michael Nall - PRE
- Timothy Kennedy - CFO
- Darrell Taylor - SVP
- Michael Dugan - SVP
- Michael Terry - SVP
- Michael Brown - CCO
- Antonio Paternostro - VPR
- Gary Marchetti - OTH
- Tom Nauman - OTH
- Tim Schofield - OTH
- David Hale - DRC
- Antonino Morales - DRC
- Linda Rubinstein - DRC
- Marsha Chandler - IND
- Bruce Gerhardt - IND
- Ivor Royston - IND